News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tikcro Technologies Announces Results of BioCancell Therapeutics' US FDA Phase I/IIa Pancreatic Cancer Trial



11/2/2010 10:17:46 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF) today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer. The trial demonstrated a significant decrease in local pancreatic tumors and no appearance of metastatic disease in most patients treated with the higher of two dosages tested after one month and three months.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES